Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for TFRC returned no results
Showing 1451 to 1500 of 2468 results for term

  1. Suicide prevention (QS189)

    This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.

  2. Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia (TA552)

    Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia in adults.

  3. Hysteroscopic removal of submucosal fibroids compared with other uterine-sparing treatments for HMB:- Is hysteroscopic removal of submucosal fibroids more effective and cost-effective than other uterine-sparing treatments for the management of HMB?

    this technique with long-term pharmacological therapy or more invasive surgical intervention would provide information on...

  4. Guide to the methods of technology appraisal 2013 (PMG9)

    This guide provides an overview of the principles and methods of health technology assessment and appraisal within the context of the NICE appraisal process

  5. Stable angina (QS21)

    This quality standard covers diagnosing and managing stable angina in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  6. Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)

    Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.

  7. Mucoactive agents:- What is the most clinically and cost-effective dose of rhDNase (dornase alfa; recombinant human deoxyribonuclease) for people with cystic fibrosis?

    underpowered, short-term trials, in people who have had this treatment before. Consequently, it is not clear what the...

  8. Prostatitis (acute): antimicrobial prescribing (NG110)

    This guideline sets out an antimicrobial prescribing strategy for acute prostatitis. It aims to optimise antibiotic use and reduce antibiotic resistance.

  9. Balloon kyphoplasty for vertebral compression fractures (HTG108)

    Evidence-based recommendations on balloon kyphoplasty for vertebral compression fractures. This involves inflating baloon-like devices placed into the collapsed vertebra until it reaches normal height, after which they are removed and replaced with a special cement.

  10. Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (HTG167)

    Evidence-based recommendations on intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. This involves collecting the solid components of the blood lost during an operation and transfusing it back to the same patient.

  11. Thoracoscopically assisted mitral valve surgery (HTG157)

    Evidence-based recommendations on thoracoscopically assisted mitral valve surgery. This involves repairing a defective valve through one or more small incisions between the ribs rather than one large incision through the breastbone (sternum).

  12. Minimally invasive total hip replacement (HTG236)

    Evidence-based recommendations on minimally invasive total hip replacement. This involves replacing the damaged hip joint (the top part of the upper leg bone and the socket in the hip bone that it fits into) with an artificial one.

  13. Endoscopic mucosal resection and endoscopic submucosal dissection of non-ampullary duodenal lesions (HTG232)

    Evidence-based recommendations on endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) of non-ampullary duodenal lesions. This involves using a long camera inserted through the mouth to view the area and removing the abnormal parts of the lining with special instruments.

  14. Transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair (HTG593)

    Evidence-based recommendations on transapical transcatheter mitral valve-in-ring implantation after failed annuloplasty for mitral valve repair in adults. This involves inserting a bioprosthetic mitral valve into an existing mitral valve ring to treat a leaking mitral valve, without needing repeat open heart surgery.

  15. Point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease (MIB132)

    NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .

  16. Hypertension in adults (QS28)

    This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.

  17. Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.

  18. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  19. Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (TA1103)

    Evidence-based recommendations on lorlatinib (Lorviqua) for treating ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor in adults.

  20. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)

    This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.

  21. Attention deficit hyperactivity disorder (QS39)

    This quality standard covers diagnosing and managing attention deficit hyperactivity disorder (ADHD) in adults, young people and children (aged 3 and over). It describes high-quality care in priority areas for improvement.

  22. Chronic kidney disease in adults (QS5)

    This quality standard covers the assessment and management of chronic kidney disease in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  23. Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over (TA949)

    Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.

  24. Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderate to severe rheumatoid arthritis in adults.

  25. Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency (TA1117)

    Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.

  26. Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

    Evidence-based recommendations on vedolizumab (Entyvio) for previously treated moderately to severely active Crohn’s disease in adults.

  27. Gastro-oesophageal reflux in children and young people (QS112)

    This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

  28. Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)

    Evidence-based recommendations on Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (excessive salivation and drooling) caused by neurological conditions in adults.

  29. Granulox for managing chronic non-healing wounds (MIB296)

    NICE has developed a medtech innovation briefing (MIB) on Granulox for managing chronic non-healing wounds .

  30. Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

    Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

  31. Oral health: local authorities and partners (PH55)

    This guideline covers improving oral health by developing and implementing a strategy that meets the needs of people in the local community. It aims to promote and protect people’s oral health by improving their diet and oral hygiene, and by encouraging them to visit the dentist regularly.

  32. Anaphylaxis: assessment and referral after emergency treatment (CG134)

    This guideline covers assessment and referral for anaphylaxis. It aims to improve the quality of care for people with suspected anaphylaxis by detailing the assessments that are needed and recommending referral to specialist allergy services.

  33. Urinary tract infection in children and young people (QS36)

    This quality standard covers diagnosing and managing urinary tract infection in infants, children and young people (under 16). It includes new and recurrent infections of the upper or lower urinary tract. It describes high-quality care in priority areas for improvement.

  34. Combined interventions for adults with social anxiety disorder:- What is the clinical and cost effectiveness of combined psychological and pharmacological interventions compared with either intervention alone in the treatment of adults with social anxiety disorder?

    treatments. The study will also provide important information on the long-term benefits of medication. This question should be addressed...

  35. What is the optimum time between follow‑up appointments for people who have had shoulder replacement, who should lead follow‑up and how this should be organised between hospital and community care?

    Full details of the research recommendation are in evidence review T: long-term follow-up and monitoring . Why the committee were unable...

  36. Are there subgroups of people with Graves' disease who have a particularly good response to antithyroid drugs?

    suggested that radioactive iodine produced better long-term outcomes than antithyroid drugs in terms of thyroid status, but...

  37. What is the clinical and cost effectiveness of dosimetry-guided radioactive iodine strategies for hyperthyroidism?

    suggested that radioactive iodine produced better long-term outcomes than antithyroid drugs in terms of thyroid status, but...

  38. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  39. Blood transfusion (QS138)

    This quality standard covers the general principles of blood transfusion in adults, young people and children over 1 year old. It describes high-quality care in priority areas for improvement. It does not cover specific conditions that blood transfusion is used for.

  40. Lyme disease (QS186)

    This quality standard covers diagnosing and managing Lyme disease in people of all ages. It also includes raising public awareness about prevention. It describes high-quality care in priority areas for improvement.

  41. Headaches in over 12s (QS42)

    This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.

  42. Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms (HTG287)

    Evidence-based recommendations on the Pipeline Flex embolisation device with Shield Technology for the treatment of complex intracranial aneurysms.

  43. Endoscopic full thickness removal of non-lifting colonic polyps (HTG439)

    Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.

  44. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  45. Differential target multiplexed spinal cord stimulation for chronic lower back and leg pain (MIB305)

    NICE has developed a medtech innovation briefing (MIB) on differential target multiplexed spinal cord stimulation for chronic lower back and leg pain .

  46. Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA327)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.

  47. Duration and intensity of home-based intermediate care:- How effective and cost effective are different approaches, in terms of duration and intensity, to providing home-based intermediate care for adults?

    intermediate care:- How effective and cost effective are different approaches, in terms of duration and intensity, to providing...

  48. Decision-making and mental capacity (NG108)

    This guideline covers decision-making in people 16 years and over who may lack capacity now or in the future. It aims to help health and social care practitioners support people to make their own decisions where they have the capacity to do so. It also helps practitioners to keep people who lack capacity at the centre of the decision-making process.

  49. Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making